Article
Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status.
International journal of cancer - 3 Nov 1995
Andersson M, Wallin H, Jönsson M, Nielsen L L, Visfeldt J, Vyberg M, Bennett W P, De Benedetti V M, Travis L B, Storm H H
Abstract excerpt
In a previous registry-based survey of 999 patients injected with alpha-emitting 232ThO2 (Thorotrast), we identified elevated risks for lung carcinoma and malignant mesothelioma. Since injected Thorotrast is retained lifelong mostly in liver, spleen and lymph nodes, the mesothelial surfaces of these organs are constantly irradiated. Thorotrast-administered patients also perpetually exhale 220Rn, a 232Th-daughter....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.